The ADC payload landscape is shifting rapidly. Driven by clinical successes of lower potency topoisomerase I inhibitors and as payloads that elicit novel modes of action continue to gain momentum ...

During the preclinical and clinical phases of ADC drug development, these payload antibodies are utilized to assess the safety and efficacy of ADCs, thereby expediting the development process.

Rise of Antibody-Drug Conjugates (ADCs) Antibody-Drug Conjugates (ADCs) are revolutionizing cancer therapy by merging the precision of targeted treatment with the potency of cytotoxic agents.